Detecting Recurrent Prostate Cancer With 11C-choline Positron Emission Tomography
- Conditions
- Prostate CancerRecurrent Prostate Cancer
- Registration Number
- NCT02531672
- Lead Sponsor
- Memorial Sloan Kettering Cancer Center
- Brief Summary
The purpose of this study is to use a new imaging drug called 11C-choline that is used with a PET/CT scan to see prostate cancer when it cannot be seen well on other scans, such as bone scans, CT or MRI.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- NO_LONGER_AVAILABLE
- Sex
- Male
- Target Recruitment
- Not specified
-
Patient must have biopsy-proven adenocarcinoma of the prostate initially treated with curative intent (surgery and radiation therapy are most common treatments but other treatments are also eligible).
-
Biochemical recurrence defined as any of the following:
- PSA ≥ 0.2 ng/mL in at least two sequential tests for patients treated with surgery.
- PSA ≥ 0.2 ng/mL above the post therapy nadir for patients treated with radiation therapy, brachytherapy or cryotherapy.
- PSA ≥ 0.2 ng/ml above the most recent therapy nadir for patients who have received additional treatment in the recurrent setting
-
Patient must have undergone standard-of-care restaging that does not clearly identify site(s) of active disease, or such prior studies must show equivocal findings for which further work-up is considered necessary to make clinical decision. Standard staging examinations may include one or more of the following: CT or MRI, bone imaging (either Tc-99m bisphosphonate scintigraphy MDP or F-18 sodium fluoride PET), FDG PET, or In-111 capromab pendetide scintigraphy no older than 3 months of consent date.
-
Age ≥ 18 years.
-
Patient must be able to tolerate PET/CT imaging.
-
Patient must be able to understand and willing to sign a written informed consent document.
- Patient must not have claustrophobia that would preclude PET/CT imaging or other contraindications to CT imaging.
Study & Design
- Study Type
- EXPANDED_ACCESS
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method
Trial Locations
- Locations (5)
Memoral Sloan Kettering Basking Ridge (Consent Only)
🇺🇸Basking Ridge, New Jersey, United States
Memorial Sloan Kettering Bergen (Consent only )
🇺🇸Montvale, New Jersey, United States
Memorial Sloan Kettering Cancer Center @ Commack (Consent Only)
🇺🇸Commack, New York, United States
Memoral Sloan Kettering Westchester (Consent only)
🇺🇸Harrison, New York, United States
Memorial Sloan Kettering Cancer Center
🇺🇸New York, New York, United States